XTL Biopharmaceuticals Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Noam Band
- Full Time Employees
- 6
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 85 Medinat Hayehudim St. Ramat Gan TA Israel 4676670
- IPO Date
- Sep 1, 2000
- Website
- xtlbio.com
- Similar Companies
- Business
- XTL Biopharmaceuticals Ltd. is an Israel-based biopharmaceutical company that acquires, in-licenses, and develops late-stage pharmaceutical product candidates addressing unmet clinical needs in autoimmune diseases and other therapeutic areas; its lead product candidate is hCDR1, a Phase II-ready peptide therapeutic under exclusive license from Yeda Research and Development Company Limited for the treatment of systemic lupus erythematosus and Sjogren’s syndrome; the pipeline also includes recombinant human erythropoietin (rHuEPO) for multiple myeloma and additional clinical-stage compounds identified through systematic validation processes. The company, formerly known as Xenograft Technologies Ltd., was founded in 1993 and is headquartered in Ramat Gan, Israel, with operations focused primarily in Israel and listed on the Nasdaq and Tel Aviv Stock Exchange under the ticker XTLB. In late 2024, XTL Biopharmaceuticals completed the acquisition of The Social Proxy Ltd., an AI-driven web data solutions provider, for $5.8 million in cash and shares, marking a strategic diversification into high-potential technology assets and funded by a $1.5 million private placement; this transaction amended prior terms amid disputes and positions the company to broaden its portfolio beyond biopharmaceuticals.
Company News
Burning Rock Biotech (NASDAQ:BNR) and XTL Biopharmaceuticals (NASDAQ:XTLB) Critical Analysis
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Update
DBV Technologies (NASDAQ:DBVT) versus XTL Biopharmaceuticals (NASDAQ:XTLB) Financial Analysis
XTL Biopharmaceuticals (NASDAQ:XTLB) Shares Pass Above Fifty Day Moving Average – Here’s Why
XTL Completed the Acquisition of Psyga Bio Ltd.
XTL Completed the Acquisition of Psyga Bio Ltd.
XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
XTL Biopharmaceuticals Announces ADS Ratio Change
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
XTL Update on Recent Developments
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
XTL Entered Definitive Agreement to Acquire The Social Proxy
XTL To Aquire The Social Proxy
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel